|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
A look at the drugs Chinese companies are presenting at ASCO this year illustrates the transformation of that nation’s biotech industry. Instead of a “me-too” drug, Lei Lei Wu notes that a Chinese company is presenting data on a potentially transformative product.
Also, readers: We'll be sending out our afternoon newsletter a bit later than usual today, to coincide with the lift of embargoes on data coming out of ASCO. We'll be in your inbox just after 5 p.m. ET today. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
 |
|
|
|
by Lei Lei Wu
|
It’s no secret that Akeso’s presentation will be one of the most closely watched readouts from the American Society of Clinical Oncology annual meeting this... | |
|
|
|
|
|
|
by Andrew Dunn
|
Over a 35-year history, Incyte has grown into a $19 billion biopharma company. The Delaware-based drugmaker is now turning to AI to power through the... | |
|
|
|
|
|
|
by Elizabeth Cairns
|
BioMarin Pharmaceutical will seek expanded approval for its bone growth-stimulating drug Voxzogo after the shot improved growth speed in children with a form of short... | |
|
|
|
|
|
|
|
|
by Elizabeth Cairns
|
Many developers of obesity drugs are fond of saying that it’s not a competition to produce the strongest and fastest level of weight loss. They... | |
|
|
|
|
|
|
by Kyle LaHucik
|
The money continues to flow for drug development startups that are working on inflammatory and immunology medicines licensed from other companies. A new San Diego... | |
|
|
|
|
|
